← Insider Monitor
SELLAS Life Sciences Group, Inc. logo
SLS

SELLAS Life Sciences Group, Inc.

Nasdaq · Pharmaceutical Preparations

3
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate galinpepimut-S, a cancer immunotherapy targeting the WT1 antigen, and additional pipeline programs aimed at treating hematologic and solid tumor malignancies.

Industry
Pharmaceutical Preparations
Headquarters
New York, NY
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Stergiou Angelos M.President and CEOSell$510KNov 18, 2026
CICIC DRAGANSVP, Chief Development OfficerSell$133KNov 18, 2026
Burns John ThomasCFOSell$73KNov 18, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for SLS.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable SLS activity by email

Free alerts for the insider and congressional trades worth watching.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.